Literatur
Sezer A et al. Lancet. 2021;397(10274):592-604
Mok TSK et al. Lancet. 2019;393(10183):1819-30
Reck M et al. J Clin Oncol. 2019;37(7):537-46
Rittmeyer A et al. Lancet. 2017;389(10066):255-65
Rosell R, Ginzaez-Cao M. Lancet. 2021;397(10274):557-9
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schalhorn, A. Phase-III-Daten zum neueren PD-1-Checkpointinhibitor Cemiplimab beim NSCLC. InFo Hämatol Onkol 24, 36–39 (2021). https://doi.org/10.1007/s15004-021-8693-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15004-021-8693-8